{"generic":"Protein C, Human","drugs":["Ceprotin","Protein C, Human"],"mono":{"0":{"id":"928779-s-0","title":"Generic Names","mono":"Protein C, Human"},"1":{"id":"928779-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928779-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Protein C deficiency disease - Purpura fulminans; Prophylaxis - Venous thrombosis; Prophylaxis:<\/b> short-term prophylaxis: initial dose, 100 to 120 IU\/kg IV followed by 3 doses at 60 to 80 IU\/kg IV every 6 hours; maintenance dose, 45 to 60 IU\/kg IV every 6 or 12 hours; maintain a trough protein C activity level above 25% for the duration of prophylaxis<\/li><li><b>Protein C deficiency disease - Purpura fulminans; Prophylaxis - Venous thrombosis; Prophylaxis:<\/b> long-term prophylaxis: 45 to 60 IU\/kg IV every 12 hours; maintain a trough protein C activity level above 25% for the duration of prophylaxis<\/li><li><b>Protein C deficiency disease - Purpura fulminans - Venous thrombosis:<\/b> initial: 100 to 120 IU\/kg IV; followed by 3 doses at 60 to 80 IU\/kg every 6 hrs; after the initial dose adjust dose to a target peak protein C activity of 100%<\/li><li><b>Protein C deficiency disease - Purpura fulminans - Venous thrombosis:<\/b> maintenance: 45 to 60 IU\/kg IV every 6 or 12 hours; once the acute episode resolves, maintain trough protein C activity level above 25% for the duration of treatment<\/li><\/ul>"},"1":{"id":"928779-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Protein C deficiency disease - Purpura fulminans; Prophylaxis - Venous thrombosis; Prophylaxis:<\/b> (neonatal and pediatric patients) short-term prophylaxis: initial dose, 100 to 120 IU\/kg IV followed by 3 doses at 60 to 80 IU\/kg IV every 6 hours; maintenance dose, 45 to 60 IU\/kg IV every 6 or 12 hours; maintain a trough protein C activity level above 25% for the duration of prophylaxis<\/li><li><b>Protein C deficiency disease - Purpura fulminans; Prophylaxis - Venous thrombosis; Prophylaxis:<\/b> (neonatal and pediatric patients) long-term prophylaxis: 45 to 60 IU\/kg IV every 12 hours; maintain a trough protein C activity level above 25% for the duration of prophylaxis<\/li><li><b>Protein C deficiency disease - Purpura fulminans - Venous thrombosis:<\/b> (neonatal and pediatric patients)  initial: 100 to 120 IU\/kg IV; followed by 3 doses at 60 to 80 IU\/kg every 6 hrs; after the initial dose adjust dose to a target peak protein C activity of 100%<\/li><li><b>Protein C deficiency disease - Purpura fulminans - Venous thrombosis:<\/b> (neonatal and pediatric patients) maintenance: 45 to 60 IU\/kg IV every 6 or 12 hours; once the acute episode resolves, maintain trough protein C activity level above 25% for the duration of treatment<\/li><\/ul>"},"3":{"id":"928779-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Protein C deficiency disease - Purpura fulminans; Prophylaxis - Venous thrombosis; Prophylaxis<\/li><li>Protein C deficiency disease - Purpura fulminans - Venous thrombosis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Meningococcemia - Purpura fulminans<br\/>"}}},"3":{"id":"928779-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928779-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"928779-s-3-10","title":"Precautions","mono":"<ul><li>concomitant anticoagulant use; increased risk of bleeding episodes<\/li><li>hypersensitivity, history or serious allergic reaction to mouse proteins and\/or heparin<\/li><li>human plasma derivative; infectious agent risk, including viruses and theoretical risk of Creutzfeldt-Jakob disease<\/li><li>immunocompromised patients;  risk of infection with human parvovirus or hepatitis A transmission<\/li><li>low-sodium diet; the maximum daily dose of Ceprotin(TM) contains over 200 mg of sodium<\/li><li>pregnancy; risk of fetal infection with human parvovirus or hepatitis A transmission<\/li><li>renal impairment; risk of sodium overload<\/li><li>thrombocytopenia, heparin-induced; Ceprotin(TM) contains a trace amount heparin<\/li><li>suspected product-related infections or other adverse reactions should be reported by the healthcare provider to Baxter Healthcare Corporation at 1-866-888-2472 or to the Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"928779-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"928779-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"928779-s-4","title":"Drug Interactions","sub":{"1":{"id":"928779-s-4-14","title":"Major","mono":"<ul><li>Abciximab (theoretical)<\/li><li>Aceclofenac (theoretical)<\/li><li>Acemetacin (theoretical)<\/li><li>Alipogene Tiparvovec (theoretical)<\/li><li>Alteplase, Recombinant (theoretical)<\/li><li>Amtolmetin Guacil (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Anistreplase (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Aspirin (theoretical)<\/li><li>Bromfenac (theoretical)<\/li><li>Bufexamac (theoretical)<\/li><li>Celecoxib (theoretical)<\/li><li>Choline Salicylate (theoretical)<\/li><li>Clonixin (theoretical)<\/li><li>Clopidogrel (theoretical)<\/li><li>Collagenase, Clostridium histolyticum (theoretical)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dexibuprofen (theoretical)<\/li><li>Dexketoprofen (theoretical)<\/li><li>Diclofenac (theoretical)<\/li><li>Diflunisal (theoretical)<\/li><li>Dipyridamole (theoretical)<\/li><li>Dipyrone (theoretical)<\/li><li>Edoxaban (theoretical)<\/li><li>Eptifibatide (theoretical)<\/li><li>Etodolac (theoretical)<\/li><li>Etofenamate (theoretical)<\/li><li>Etoricoxib (theoretical)<\/li><li>Felbinac (theoretical)<\/li><li>Fenofibrate (theoretical)<\/li><li>Fenoprofen (theoretical)<\/li><li>Fepradinol (theoretical)<\/li><li>Feprazone (theoretical)<\/li><li>Floctafenine (theoretical)<\/li><li>Flufenamic Acid (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Flurbiprofen (theoretical)<\/li><li>Ibuprofen (theoretical)<\/li><li>Ibuprofen Lysine (theoretical)<\/li><li>Iloprost (theoretical)<\/li><li>Indomethacin (theoretical)<\/li><li>Ketoprofen (theoretical)<\/li><li>Ketorolac (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Lornoxicam (theoretical)<\/li><li>Loxoprofen (theoretical)<\/li><li>Lumiracoxib (theoretical)<\/li><li>Meclofenamate (theoretical)<\/li><li>Mefenamic Acid (theoretical)<\/li><li>Meloxicam (theoretical)<\/li><li>Morniflumate (theoretical)<\/li><li>Nabumetone (theoretical)<\/li><li>Naproxen (theoretical)<\/li><li>Nepafenac (theoretical)<\/li><li>Niflumic Acid (theoretical)<\/li><li>Nimesulide (theoretical)<\/li><li>Nintedanib (theoretical)<\/li><li>Oxaprozin (theoretical)<\/li><li>Oxyphenbutazone (theoretical)<\/li><li>Parecoxib (theoretical)<\/li><li>Pentosan Polysulfate Sodium (theoretical)<\/li><li>Phenylbutazone (theoretical)<\/li><li>Piketoprofen (theoretical)<\/li><li>Piroxicam (theoretical)<\/li><li>Prasugrel (theoretical)<\/li><li>Proglumetacin (theoretical)<\/li><li>Propionic Acid (theoretical)<\/li><li>Propyphenazone (theoretical)<\/li><li>Proquazone (theoretical)<\/li><li>Reteplase, Recombinant (theoretical)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Rofecoxib (theoretical)<\/li><li>Salicylic Acid (theoretical)<\/li><li>Salsalate (theoretical)<\/li><li>Sodium Salicylate (theoretical)<\/li><li>Streptokinase (theoretical)<\/li><li>Sulfinpyrazone (theoretical)<\/li><li>Sulindac (theoretical)<\/li><li>Tenecteplase (theoretical)<\/li><li>Tenoxicam (theoretical)<\/li><li>Tiaprofenic Acid (theoretical)<\/li><li>Ticlopidine (theoretical)<\/li><li>Tirofiban (theoretical)<\/li><li>Tolfenamic Acid (theoretical)<\/li><li>Tolmetin (theoretical)<\/li><li>Treprostinil (theoretical)<\/li><li>Urokinase (theoretical)<\/li><li>Valdecoxib (theoretical)<\/li><li>Vilazodone (theoretical)<\/li><li>Vorapaxar (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><\/ul>"}}},"5":{"id":"928779-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Itching, Rash<\/li><li><b>Neurologic:<\/b>Lightheadedness (less than 1%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Hypotension<\/li><li><b>Hematologic:<\/b>Heparin-induced thrombocytopenia<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction (less than 1%)<\/li><li><b>Respiratory:<\/b>Hemothorax<\/li><\/ul>"},"6":{"id":"928779-s-6","title":"Drug Name Info","sub":{"0":{"id":"928779-s-6-17","title":"US Trade Names","mono":"Ceprotin<br\/>"},"2":{"id":"928779-s-6-19","title":"Class","mono":"Anticoagulant<br\/>"},"3":{"id":"928779-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928779-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"928779-s-7","title":"Mechanism Of Action","mono":"Once activated, protein C (a precursor of a vitamin K-dependent anticoagulant glycoprotein) inactivates the activated forms of factors V and VIII with subsequent reduction in thrombin formation. Other effects include profibrinolytic effects <br\/>"},"8":{"id":"928779-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"928779-s-8-24","title":"Distribution","mono":"Vd: IV, 0.74 dL\/kg <br\/>"},"4":{"id":"928779-s-8-27","title":"Elimination Half Life","mono":"9.9 hours <br\/>"}}},"9":{"id":"928779-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>reconstitute with sterile water for injection at room temperature<\/li><li>use within 3 hours after reconstitution<\/li><li>filter the content with a filter needle before administration<\/li><li>administer at room temperature<\/li><li>for children less than 10 kg, the maximum rate of infusion is 0.2 mL\/kg\/minute; for children greater than 10 kg and adults the maximum rate of infusion is 2 mL\/minute.<\/li><\/ul>"},"10":{"id":"928779-s-10","title":"Monitoring","mono":"<ul><li>protein C activity levels before and during treatment; during acute thrombotic events, measure protein C activity immediately before the next dose until the patient is stabilized<\/li><li>target peak protein C activity at 100% during acute episodes and maintain trough protein C activity level above 25% after resolution of acute episode or for prophylaxis<\/li><li>coagulation parameters.<\/li><li>sodium concentration.<\/li><\/ul>"},"11":{"id":"928779-s-11","title":"How Supplied","mono":"<b>Ceprotin<\/b><br\/>Intravenous Powder for Solution: 1 IU<br\/>"},"13":{"id":"928779-s-13","title":"Clinical Teaching","mono":"<ul><li>Despite screening and testing, human plasma products carry a remote risk of transmitting infectious agents. Risks and benefits should be discussed with patient by healthcare professional.<\/li><li>Inform patient that the quantity of sodium in the maximum daily dose of Ceprotin(TM) exceeds 200 mg. Instruct patient to follow a low-sodium diet.<\/li><li>This drug may cause rash, itching, and lightheadedness.<\/li><li>Advise patient to report signs\/symptoms of a hypersensitivity reaction.<\/li><li>Instruct patient to report signs\/symptoms of heparin-induced thrombocytopenia. Ceprotin(TM) contains trace amounts of heparin.<\/li><\/ul>"}}}